Document:

HEI 5.25% Medium Term Note, Series D due 3/7/08

HEI Exhibit 4(b) 
 
        UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR
NOTES IN CERTIFICATED FORM, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY (THE “DEPOSITARY”) TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR
BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (55 WATER STREET, NEW YORK, NEW YORK) TO
THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY AND ANY
PAYMENT IS MADE TO CEDE & CO., ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
 
HAWAIIAN ELECTRIC INDUSTRIES, INC. 
MEDIUM-TERM NOTE, SERIES D 
(Fixed Rate) 
 

	 CUSIP No. 41987QBB8
	 	 Principal Amount:  $50,000,000

	
	 FXR No. 27
	 	 Stated Maturity Date:  March 7, 2013

	
	 Original Issue Date: March 7, 2003
	 	 Redemption Commencement Date:  N/A

	
	 Interest Rate: 5.25%
	 	 Initial Redemption Percentage:  N/A

	
	 Interest Payment Date(s):
	 	 Annual Redemption Percentage Reduction:  N/A

	             March 7 and September
7,
	 	 
	             commencing September 7,
2003
	 	 
	
	 [    ]     Check if a Discount Note
	 	 Other Provisions:  N/A

	                 Issue
Price:
	 	 
	
	 	 	 Addendum
Attached:  [    ]  Yes    [ X ]  No

	
	 Optional Repayment Date(s): N/A
	 	 

 
        HAWAIIAN ELECTRIC INDUSTRIES, INC., a corporation duly organized and existing under the laws of Hawaii (hereinafter called “Company”, which term includes any successor
corporation under the Indenture hereinafter referred to), for value received, hereby promises to pay to CEDE & CO., or registered assigns, the principal sum of 
 
****FIFTY MILLION DOLLARS**** 

on the Stated Maturity Date specified above, and to pay interest thereon from the Original Issue Date
specified above or from the most recent Interest Payment Date to which interest has been paid or duly provided for, periodically on the Interest Payment Date or Dates specified above, commencing with the first such Interest Payment Date next
succeeding the Original Issue Date specified above, and on the Stated Maturity Date (hereinafter sometimes referred to as “Maturity”), at the Interest Rate per annum set forth above, until the principal hereof is paid or made available for
payment, and at the Interest Rate per annum set forth above on any overdue premium and (to the extent that the payment of such interest shall be legally enforceable) on any overdue installment of interest; provided, however, that if
such Original Issue Date is after the Regular Record Date and before the Interest Payment Date immediately following such Regular Record Date, interest payments will commence on the second Interest Payment Date following the Original Issue Date to
the Holder of this Note on the Regular Record Date with respect to such second Interest Payment Date. Interest on this Note will be computed on the basis of a 360-day year of twelve 30-day months. 
 
        Interest on
this Note will accrue from and including the immediately preceding Interest Payment Date in respect of which interest has been paid or duly made available for payment (or from and including the Original Issue Date if no interest has been paid or
duly made available for payment) to, but excluding, the applicable Interest Payment Date or Maturity, as the case may be. If any Interest Payment Date or the Maturity of this Note falls on a day that is not a Business Day, the related payment of
principal, premium, if any, and/or interest need not be made on such day, but may be made on the next succeeding Business Day as if made on the date such payment was due, and no additional interest will accrue in respect of the payment made on that
next succeeding Business Day. The interest so payable, and punctually paid or duly made available for payment, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Note (or one or more
Predecessor Notes) is registered at the close of business on the Regular Record Date for each Interest Payment Date, which date (whether or not a Business Day), shall be 15 calendar days next preceding each such Interest Payment Date; provided,
however, that interest payable at Maturity will be payable to the Person to whom the principal hereof will be payable. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular
Record Date and may either be paid to the Person in whose name this Note (or one or more Predecessor Notes) is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice
whereof shall be given to Holders of Notes not less than 10 calendar days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Notes of
this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture. As used herein, “Business Day” means any day other than a Saturday or Sunday or any other day on which banks
in The City of New York are generally authorized or obligated by law or executive order to close. 
 
        This Note is one of a duly authorized issue of securities of the Company (herein called
the “Securities”, and the series thereof to which this Note belongs being herein called the “Notes”), issued and to be issued in one or more series under an Indenture dated as of October 15, 1988, as supplemented by a Third
Supplemental Indenture, dated as of August 1, 
 

2 

2002 (as so supplemented, hereinafter called the “Indenture”), between the Company and Citibank,
N.A., as trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of the respective rights,
limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Notes and of the terms upon which the Notes are, and are to be, authenticated and delivered. This Note is one of the series designated above.
The Notes of this series may be issued from time to time at varying maturities (between nine months and thirty years from the Original Issue Date specified above) and interest rates and in an aggregate principal amount up to $300,000,000.

 
        Payments of the principal (and premium, if any) and interest due with respect to this Note, if issued in book-entry form, will be made by the Company through the Trustee to The
Depository Trust Company, or other depositary selected by the Company, consistent with procedures agreed to by the Company and such depositary. Payments of the principal (and premium, if any) and interest due at Maturity with respect to this Note,
if issued in certificated form, will be made in immediately available funds upon presentation and surrender of such Note at the Corporate Trust Office of the Trustee or other Paying Agent, provided, however, that this Note is presented
to the Trustee or other Paying Agent in time for the Trustee or other Paying Agent to make such payments in such funds in accordance with its normal procedures. Payments of interest other than at Maturity with respect to this Note, if issued in
certificated form, will be made at the Corporate Trust Office; provided, however, that the payment of such interest may be made at the option of the Company by check mailed to the address of the Person entitled thereto as such address
shall appear in the Security Register. Notwithstanding the foregoing, a Holder of $10,000,000 or more in aggregate principal amount of Notes issued in certificated form and having the same Interest Payment Dates will be entitled to receive interest
payments (other than at Maturity) by wire transfer of immediately available funds if appropriate wire transfer instructions have been received in writing by the Trustee not less than 15 calendar days prior to the applicable Interest Payment Date
(any such wire transfer instructions received by the Trustee to remain in effect until revoked in writing by such Holder). 
 
        This Note will not be subject to any sinking fund and will not be redeemable at the option
of the Company nor repayable at the option of the Holder hereof prior to the Stated Maturity Date. 
 
        The Indenture contains provisions for defeasance at any time of (a) the entire
indebtedness of this Note and (b) certain restrictive covenants, in each case upon compliance by the Company with certain conditions set forth therein, which provisions apply to this Note. 
 
        If an Event of Default with respect to Notes of this series
shall occur and be continuing, the principal of the Notes of this series may be declared due and payable in the manner and with the effect provided in the Indenture. 
 
        The Indenture permits, with certain exceptions as therein
provided, the amendment thereof and the modification of the rights and obligations of the Company and the right of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the
consent of the Holders of 66-2/3% in principal amount 
 

3 

 
of the Securities at the time
Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all
Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Note shall be conclusive
and binding upon such Holder and upon all future Holders of this Note and of any Note issued upon the registration of transfer hereof or in exchange hereof or in lieu hereof, whether or not notation of such consent or waiver is made upon this Note.

 
        No reference herein to the Indenture and no provision of this Note or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay
the principal of (and premium, if any) and interest on this Note at the times, places and rate, and in the coin or currency, herein prescribed. 
 
        As provided in the Indenture and subject to certain limitations therein and herein set
forth, the transfer of this Note is registrable in the Security Register upon surrender of this Note for registration of transfer at the office or agency of the Company in any place where the principal of (and premium, if any) and interest on this
Note are payable duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by the Holder hereof or his attorney duly authorized in writing, and thereupon one or
more new Notes of this series of like tenor, of authorized denominations and for the same aggregate principal amount will be issued to the designated transferee or transferees. 
 
        Unless otherwise set forth above, the Notes of this series
are issuable only in registered form, without coupons, in minimum denominations of $1,000 and any amount in excess thereof that is an integral multiple of $1,000. As provided in the Indenture and subject to certain limitations therein and herein set
forth, Notes of this series are exchangeable for a like aggregate principal amount of Notes of this series of like tenor of a different authorized denomination, as requested by the Holder surrendering the same. 
 
        No service
charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 
 
        Prior to due
presentment of this Note for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Note is registered as the owner hereof for all purposes, whether or not this Note is
overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 
 
        All terms used in this Note which are defined in the Indenture shall have the meanings
assigned to them in the Indenture. 
 

4 

 
        Unless the certificate of authentication hereon has been executed by the Trustee by manual signature, this Note shall not be entitled to any benefit under the Indenture or be valid or
obligatory for any purpose. 
 
        This Note will for all purposes be governed by, and construed in accordance with, the laws of the State of New York. 
 

5 

 
        IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its corporate seal. 
 
Dated: March 7, 2003 
 

	 	 	 	 	 HAWAIIAN ELECTRIC INDUSTRIES, INC.

	
	 [CORPORATE SEAL]
	 	 	 	 By:
	 	 /s/    ERIC K.
YEAMAN        

	 	 	 	 	 	 	 	 	 Eric K. Yeaman
 Financial Vice President, Treasurer
         and Chief Financial
Officer

	 	 	 	 	 
	
	 	 	 	 	 By:
	 	 /s/    CURTIS Y.
HARADA        

	 	 	 	 	 	 	 	 	 Curtis Y. Harada
 Controller and Chief Accounting Officer

 
TRUSTEE’S CERTIFICATE OF AUTHENTICATION 
 
This is one of the Securities of the series designated therein referred to in the within mentioned Indenture. 
 

	 CITIBANK, N.A., as Trustee

	
	 By:
	 	 /s/    PATRICK DE
FELICE        

	 	 	 Authorized Officer

 

6 

ABBREVIATIONS 
 
        The following abbreviations, when used in the inscription
specified in this instrument, shall be construed as though they were written out in full according to applicable laws or regulations. 
 

	 TEN COM — as tenants in common

	
	 UNIF GIFT MIN ACT — ______________________ Custodian ______________________

	                                       
                                        
                                        
  (Minor)

	
	 Under Uniform Gifts to Minors Act

	
	 _____________________________

	 (State)

	
	 TEN ENT —   as tenants by the entireties

	
	 JT TEN —       as joint tenants with right of survivorship and not as tenants in
common

 
        Additional abbreviations may also be used though not in the above list. 
 

 
        FOR VALUE RECEIVED, the undersigned hereby sell(s), assign(s) and transfers unto 
 
Please Insert Social Security or Other 
Identifying Number of-Assignee: 
 

 
 

 
PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS 
INCLUDING ZIP CODE OF ASSIGNEE: 
 

 
 

 
 

 
the within Note and all rights hereunder, hereby irrevocably constituting and appointing 
 
 

 
attorney to transfer said Note on the books of the Company, with full power of substitution in the premises. 
 
Dated:    ______________________________________________            _____________________________________________ 
 
NOTICE:  The signature to this assignment must correspond with the
name as specified in the within instrument in every particular, without alteration or enlargement, or any change whatsoever.Agreement between Amgen Inc. and Edward Fritzky

  Exhibit 10.82
  AMENDED AND RESTATED EMPLOYMENT AGREEMENT
            AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of the Effective Date (as defined below), as amended and restated as of January 2,
2003, between Amgen Inc., a Delaware corporation (the “Company”), and Edward V. Fritzky (the “Executive”).  This Agreement amends and restates in its entirety the Employment Agreement, dated as of the Effective Date, between
the Company and the Executive (the “Original Agreement”).  References herein to this “Agreement” shall refer to the Original Agreement, as hereby amended and restated;
            WHEREAS, prior to the consummation of the Merger (as defined below), the Executive was employed by Immunex  Corporation (“Immunex Corporation”) as its
Chief Executive Officer, and the Executive possesses intimate knowledge of the business and affairs of Immunex Corporation and has acquired certain confidential information and data with respect to Immunex Corporation;
            WHEREAS, pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of December 16, 2001 by among the Company, Immunex Corporation and a subsidiary
of the Company (“Merger Sub”) (the “Merger Agreement”), Merger Sub merged with and into Immunex Corporation (the “Merger”);
           WHEREAS, the Company has determined that it is of the utmost importance to assure itself of retaining the Executive’s services during the critical period
following the Merger to assist in the integration of the operations of the Company and Immunex Corporation;
 
 

             WHEREAS, the Company desires to secure the continued employment of the Executive in accordance herewith, effective
upon the date of the consummation of the Merger pursuant to the Merger Agreement (the “Effective Date”); 
            WHEREAS, the Executive
was a participant in the Immunex  Corporation Leadership Continuity Plan, dated as of October 25, 2001 (the “LCP”);
            WHEREAS, the Executive would have been entitled to receive certain severance payments and benefits pursuant to the LCP upon termination of employment with Immunex
Corporation following the Effective Date;
            WHEREAS, the Executive has foregone the right to receive such payments and benefits by entering
into this Agreement;
            WHEREAS, the parties now desire to enter into an agreement setting forth the terms and conditions of the employment
relationship of the Executive and the Company;
            NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and
agreements hereinafter set forth, it is hereby agreed as follows:

	           1.     Definitions.
 
	  
 
	                    (a)     “Board” shall mean the
Board of Directors of the Company.
 
	  
 
	                    (b)     “Cause” shall mean (i) the
willful and continued failure by the Executive to substantially perform the Executive’s duties with the Company (other than any such failure resulting from the Executive’s incapacity due to physical or mental illness or any such actual or
anticipated failure after the issuance of a Notice of Termination for Good Reason by the Executive pursuant to Section 14 hereof) that has not been cured within thirty (30) days after a written demand for substantial performance is delivered to the
Executive by the Board, which 
 

  2

	  demand specifically identifies the manner in which the Board believes that the Executive has not substantially performed the Executive’s duties, (ii) the willful
engaging by the Executive in conduct which is demonstrably and materially injurious to the Company or its subsidiaries, monetarily or otherwise, or (iii) a material breach by the Executive of the terms of this Agreement.  For purposes of
clauses (i) and (ii) of this definition, (x) no act, or failure to act, on the Executive’s part shall be deemed “willful” unless done, or omitted to be done, by the Executive not in good faith and without reasonable belief that the
Executive’s act, or failure to act, was in the best interest of the Company and (y) in the event of a dispute concerning the application of this provision, no claim by the Company that Cause exists shall be given effect unless the Company
establishes to the Board by clear and convincing evidence that Cause exists.
 
	  
 
	                   (c)     “Code” shall
mean the Internal Revenue Code of 1986, including any amendments thereto or successor tax codes thereof.
 
	  
 
	                    (d)     “Good Reason”
shall mean any material breach of this Agreement by the Company that has not been cured within thirty (30) days after a written demand for cure is delivered to the Company by the Executive, including without limitation:
 
	  
 
	  
 	                 (i)     the removal of the Executive from his position as a
member of the Board except in the event that such removal relates to the termination by the Company of the Executive’s employment for Cause or by reason of disability pursuant to Section 13 hereof; or
 
	  
 
	  
 	                 (ii)    failure by the Company to obtain the assumption of this
Agreement as contemplated by Section 19(a) hereof.
 

 3

	                    (e)     “Termination Date” shall
mean (i) if the Executive’s employment is terminated by the Executive’s death, the date of death; (ii) if the Executive’s employment is terminated for purposes of this Agreement by reason of disability pursuant to Section 13 hereof,
the earlier of thirty (30) days after the Notice of Termination is given or one (1) day prior to the end of the Employment Period; (iii) if the Executive’s employment is terminated by the Executive voluntarily (other than for Good Reason), the
date the Notice of Termination is given; (iv) if the Executive’s employment is terminated by the Company, whether or not for Cause, (other than by reason of disability pursuant to Section 13 hereof) or by the Executive for Good Reason, the
earlier of thirty (30) days after the Notice of Termination is given or one (1) day prior to the end of the Employment Period; and (v) if the Executive’s employment is not terminated prior to the end of the Employment Period, the date following
the last day of the Employment Period.
 
	  
 
	            2.     Employment; Employment Period.
 
	  
 
	                   (a)     On the Effective Date, the Company
shall employ the Executive, and the Executive will be employed by the Company, in accordance with the terms of this Agreement for the period set forth below (the “Employment Period”).  During the Employment Period, Executive shall be
an employee of the Company for all purposes and will not be an independent contractor.
 
	  
 
	                    (b)     The Employment Period shall commence
as of the Effective Date and shall continue until the second anniversary of the Effective Date (that second anniversary shall be the last day of the Employment Period); provided, however, that if the Merger Agreement is terminated in accordance with
its terms, then, at the time of such termination, this Agreement
 

  4

	  shall terminate and be of no force or effect.  This Agreement shall be of no force and effect unless and until the Effective Date occurs.
 
	  
 	  
 
	                   (c)     The Executive hereby
waives any right to any severance benefit otherwise payable to the Executive pursuant to the LCP.  In consideration for such waiver, on the Effective Date the Company shall pay to the Executive a cash lump sum payment equal to three times the
sum of (i) the Executive’s base salary as in effect immediately prior to the Effective Date, (ii) the Executive’s target annual incentive compensation in effect immediately prior to the Effective Date, and (iii) the value of the
contributions or the allocations made, as applicable, on behalf of the Executive to the Immunex Corporation 401(k) Savings Plan and the Immunex Corporation Nonqualified Deferred Compensation Plan in respect of the fiscal year ending immediately
prior to the fiscal year in which the Effective Date occurs.
 
	  
 
	            3.     Duties.
 
	  
 
	                    (a)     During the Employment
Period, the Executive shall serve as a strategic advisor to the Company and shall provide such other services as set forth below.  At or prior to the Effective Time (as defined in the Merger Agreement), the Board shall take all action necessary
so that, immediately following the Effective Time, the Executive shall be appointed to the Board.  If at the Effective Time the Company has multiple classes of directors, the Company shall take all action reasonably necessary, subject to
applicable law, to appoint Executive to the class of directors with the longest remaining term as of the Effective Time, provided that the Company shall not be required to request that an incumbent director of the Company switch classes.  The
Executive shall not be required to perform services hereunder for more than 20 hours per month.
 

 5

	                    (b)     In his capacity as a
strategic advisor to the Company, the Executive shall report directly to the Chief Executive Officer of the Company (the “Chief Executive Officer”) and shall have any or all of the following duties and responsibilities as determined by the
Chief Executive Officer in his discretion:
 
	  
 
	  
 	                1.     Executive shall perform such strategic advisory services as are
assigned to him by the Chief Executive Officer.
 
	  
 
	  
 	                2.     Executive shall facilitate the relationships between the
Company and Wyeth (formerly American Home Products Corporation) and shall advise appropriate Company executives regarding the Company’s operations with respect to ENBREL.
 
	  
 
	  
 	               3.     Executive shall facilitate the Company’s senior
management’s relationships with the Seattle community, and shall serve as a liaison between the Company’s senior executives and business, government and philanthropic leaders within the Seattle community.  Executive shall represent
the Company at Seattle functions designated by the Company and shall advise the Company’s senior management regarding matters related to the Seattle community.
 
	  
 
	  
 	                4.     Executive shall advise on and assess new strategic, licensing
and acquisition opportunities for the Company within the biotechnology industry, including meeting and networking with senior executives and consultants in the industry, and attending investor and other conferences.
 
	  
 
	  
 	                5.     Executive shall assist the Company in developing and enhancing
the Company’s relationships with the primary venture capital companies in the
 

  6

	  
 	 biotechnology industry.  Executive shall meet with venture capitalists to assess and help identify the best potential targets for acquisition and licensing by the
Company.
 
	  
 
	  
 	                   6.     Executive will assist Steve Odre, General
Counsel, or his designee or successor, on legal matters or litigation regarding matters involving the Company, Immunex Corporation or ENBREL with which Executive is familiar.  This assistance may include, but shall not be limited to
Executive’s meeting with Company attorneys, and testifying or otherwise appearing at depositions or court hearings scheduled as a result of any such litigation, including preparation for all the above.  Steve, or his successor, may assign
these matters to Executive from time to time.
 
	  
 
	             The duties and responsibilities of Executive and the services to be performed by Executive as set
forth above shall be consistent with the Executive’s background and experience.
 
	  
 
	                     (c)     The Chief
Executive Officer will have the right to determine the times and places where such services will be performed.  Executive will be a member of the Executive Department of the Company and, as such, the Chief Executive Officer will assign
strategic advisory and other  matters to Executive from time to time, and Executive will provide the Chief Executive Officer with written or oral reports as requested by the Chief Executive Officer (or if not requested by the Chief Executive
Officer, then periodically but not less frequently than quarterly) detailing Executive’s progress toward accomplishing the tasks and directives given to Executive by the Chief Executive Officer.  Executive will also provide additional
reports and materials, upon reasonable request by the Chief Executive Officer.  The Chief Executive Officer will evaluate Executive’s performance.
 

  7

	                    (d)     Except as set forth in Section 4,
Executive agrees that Executive will not hire or pay anyone to assist Executive in performing his services under this Agreement.  If Executive requires assistance in providing his services under this Agreement, Executive agrees to consult with
the Chief Executive Officer, and, if, in the Company’s sole discretion, it is deemed appropriate, the Company either will assign one of its then-current employees to assist Executive, or the Company will hire an employee of the Company to act
as an assistant for Executive.
 
	  
 
	                   (e)     The Chief Executive Officer will
control and direct the manner (including the order) in which Executive performs the services under this Agreement, including the details and means by which Executive provides his services.
 
	  
 
	                    (f)     If requested by the Chief Executive
Officer, Executive agrees to attend certain meetings or programs related to Executive’s area of expertise.  Furthermore, from time to time, Executive’s duties may require Executive to travel to and/or attend meetings at various
locations, including the Company’s Thousand Oaks facility, and Executive agrees that no reasonable request by the Chief Executive Officer for travel or attendance at meetings will be refused.  The Chief Executive Officer will cooperate
with Executive in scheduling any such business trips or meetings.  The Company will reimburse Executive for reasonable travel expenses pursuant to the reimbursement policy(ies) in place at the Company at the time Executive incurs such
expenses.
 
	  
 
	                    (g)     Executive will maintain an accurate
log showing the time Executive has spent performing the foregoing services and this log shall be deemed conclusive evidence of the time spent.  The Chief Executive Officer, at any time, may request a copy of Executive’s log and

 8

	  Executive agrees to provide such a copy within a reasonable period of time after the request is made.
 
	  
 
	                    (h)     During the Employment
Period, Executive may not be employed by any person or company other than the Company, without the Company’s prior approval.  Executive may, however, consult for companies that do not compete with the Company, or companies within the
fields of biotechnology and/or pharmaceutics having fewer than 500 employees and no current contractual relationship with the Company, provided that such consulting does not violate the Proprietary Information and Inventions Agreement between
Executive and the Company (the “Proprietary Agreement”) or interfere with Executive’s duties under this Agreement.  In addition, Executive may be self-employed, an independent contractor, a partner or a consultant in a venture
fund, or a founding member of a biotechnology startup, provided that such activities do not compete with the Company, violate the Proprietary Agreement or interfere with Executive’s duties under this Agreement. Executive’s engaging in the
consulting and other activities described in the preceding two sentences shall not constitute a violation of paragraph 11 of the Proprietary Agreement.  Executive also agrees that during the Employment Period he will not solicit for
employment or affiliation, including as an independent contractor, any officer, director, or employee of the Company or its subsidiaries.
 
	  
 
	                   (i)     Executive may not assign
or delegate any of his duties or responsibilities under this Agreement.
 
	  
 
	          4.       Office Space and Support Services.
 	  
 
	  
 	  
 
	                    Subject to Section 3(c), the Executive may (with the
approval of the Chief Executive Officer) perform services at rented offices and the Executive shall be reimbursed for
  
 

  9

	  rental payments for office space, subject to the limitation in the last sentence of this section.  During the Employment Period, the Executive may (with the approval of the
Chief Executive Officer) procure secretarial, communications and technology support services in connection with his employment hereunder and the Company shall reimburse the Executive for such services, subject to the limitation in the last sentence
of this section.  All expenses reimbursed to the Executive under this Section 4 shall not exceed $250,000 per year.
 
	  
 
	           5.     Compensation.  During the Employment Period, the Executive shall be
compensated as follows:
 
	  
 
	                    (a)     The Executive shall receive, in
accordance with the Company’s standard payroll policies, an annual base salary of not less than $500,000.
 
	  
 
	                    (b)     The Executive shall be entitled to
participate in all of the employee benefit plans and arrangements (including any life, death, disability, accident or health insurance plan, employee stock purchase plan, and qualified or non-qualified retirement or savings plan) made available by
the Company to senior executives of the Company, subject to and on a basis consistent with the terms, conditions and overall administration of such plans and arrangements; provided, however, that to the extent Executive’s participation in such
Company benefit plans and arrangements is precluded by the applicable terms and conditions of such plans or arrangements, the Company shall arrange to provide, at the Company’s sole expense, the Executive and anyone entitled to claim under or
through the Executive with equivalent benefits (on an after tax basis) under an alternative arrangement.  Notwithstanding the foregoing, in no event shall the Executive participate in Company’s Performance Based Management Incentive
Plan.
 

 10

	                    (c)     The Executive shall be entitled to
receive perquisites, including, without limitation, financial counseling and tax planning services by AYCO or a company providing comparable equivalent services, that are the same as or substantially equivalent to, those provided to the Executive by
Immunex Corporation immediately prior to the Effective Date.
 
	  
 
	            6.     Retention Bonus.  Effective as of the Effective Date, the Company
shall contribute a retention bonus of $1,000,000 to a deferred compensation account (the full balance of such account as of any specified date, the “Retention Bonus Account”) established for the benefit of the Executive under the
Company’s deferred compensation plan (the “Deferred Compensation Plan”).  Except to the extent otherwise provided in this Agreement, the Retention Bonus Account, and the Executive’s rights with respect thereto, shall be
subject to the terms and conditions of the Deferred Compensation Plan.  The Retention Bonus Account shall vest as follows: (a) with respect to $500,000 originally deposited (plus the related earnings and minus the related losses), on the on the
first anniversary of the Effective Date (provided the Executive is then employed by the Company), and (b) with respect to an additional $250,000 originally deposited (plus the related earnings and minus the related losses) on each of (i) the date 18
months immediately following the Effective Date and (ii) the second anniversary of the Effective Date (in each case provided the Executive is the employed by the Company).  Except as provided in Sections 10, 11, 12 and 13, the Retention Bonus
Account shall be paid to the Executive upon the second anniversary of the Effective Date, provided that the Executive is employed with the Company on such date.
 

 11

	            7.     Equity Grants.
 
	  
 
	                    (a)     The Company shall grant to the
Executive, effective as of the Effective Date, a non-qualified stock option (the “Option”) to purchase 450,000 shares of the common stock of the Company par value $.0001 per share (“Common Stock”).  The grant shall provide
for (i) an exercise price per share equal to the fair market value of the Common Stock on the date of grant, (ii) except as provided in Sections 10, 11, 12 and 13, the vesting of the Option at the rate of one-third (1/3) of the shares of Common
Stock subject to such Option on the date of grant and one-third (1/3) on each of the first and second anniversaries of the Effective Date, (iii) an option term equal to five (5) years and (iv) in the event that the Executive’s employment with
the Company is terminated on or after the end of the Employment Period, a post-termination exercise period of the remainder of such option term.  Except as set forth in this Agreement, the Option shall be subject to the other terms and
conditions similar to those set forth in the Company’s Amended and Restated 1997 Equity Incentive Plan (the “Option Plan”) (or applied to grants to senior executives of the Company) and the applicable stock option agreement which
shall reflect the terms set forth herein and which shall be attached as Exhibit A hereto prior to the Effective Date, in form agreed upon by the parties.
 
	  
 
	                   (b)     The Company shall grant to the
Executive, effective as of the Effective Date, 100,000 shares of Common Stock, of which 66,000 shares will be restricted (such restricted portion, “Restricted Stock”).  The grant shall provide for, except as provided in Sections 10,
11, 12 and 13, the vesting of the Restricted Stock at the rate of one-half (1/2) of the shares of Restricted Stock on each of the first and second anniversaries of the Effective Date.  Except as set forth above, the Restricted Stock shall be
subject to all other terms and conditions
 

  12

	  of the Option Plan and the applicable Restricted Stock agreement which shall reflect the terms set forth herein and which shall be attached as Exhibit B hereto prior to the
Effective Date, in the form agreed upon by the parties.
 
	  
 
	            8.     Expenses.  During the Employment Period, the Company shall promptly
reimburse the Executive in accordance with the Company’s policies for all reasonable expenses (including first class travel) incurred by him in performing services pursuant to the terms of this Agreement.
 
	  
 
	           9.     Termination Benefits.  Upon the earlier to occur of (x) the
termination of the Executive’s employment for any reason or (y) the end of the Employment Period, the Executive shall be entitled to the following termination benefits (the “Termination Benefits”):
 
	  
 
	                    (a)     No later than five days following the
Termination Date, the Company shall pay to the Executive an amount equal to (i) all base salary for the time period ending with the Termination Date and (ii) any and all monies advanced in connection with the Executive’s employment for
reasonable and necessary expenses incurred by the Executive on behalf of the Company for the time period ending with the Termination Date.
 
	  
 
	                    (b)     Except in the event of a termination
by the Company for Cause or by the Executive without Good Reason, from the Termination Date until the third anniversary of the Termination Date, the Company shall arrange to provide the Executive and his dependents (i) life, death, disability,
accident and health insurance benefits substantially similar to those provided to the Executive and his dependents immediately prior to the Termination Date, at no greater after tax cost to the Executive than the after tax cost to the Executive
immediately prior to such date, and (ii) other perquisites, including, without limitation, financial counseling and tax 
 

 13

	  planning services by AYCO or a company providing comparable equivalent services, to the same extent provided to the Executive prior to the Termination Date.  Benefits
otherwise receivable by the Executive pursuant to Section 9(b)(i) shall be reduced to the extent benefits of the same type are received by or made available to the Executive during the period the Executive is eligible to receive benefits pursuant to
such section (and any such benefits received by or made available to the Executive shall be reported to the Company by the Executive); provided, however, that the Company shall reimburse the Executive for the excess, if any, of the cost of such
benefits to the Executive over such cost immediately prior to the Termination Date.
 
	  
 
	                    (c)     Except in the event of the
Executive’s death, the Company shall provide the Executive with outplacement services suitable to the Executive’s position for a period of one year commencing on the date the Executive first uses such outplacement services.

	  
 
	                    (d)     The Company shall pay or provide all
other amounts and benefits to which the Executive (or in the event of the Executive’s death, the Executive’s surviving spouse or other beneficiary) may be entitled as compensatory fringe benefits or under the terms of any benefit plan of
the Company, pursuant to the terms of the benefit plan or practice establishing such benefits.
 
	  
 
	           10.   Termination For Cause or Without Good Reason.  If the Executive’s employment
is terminated during the Employment Period by the Company for Cause or by the Executive without Good Reason, then the Executive shall be entitled to receive Termination Benefits pursuant to Section 9 and shall not receive any compensation pursuant
to Section 5 with respect to periods following the Termination Date.  Any portion of the Restricted Stock and the Option which is unvested as of the Termination Date shall be forfeited and any portion of the Option
 

  14

	  which is vested as of the Termination Date shall remain exercisable for the remainder of the original term.  In addition, no later than five (5) days following
the Termination Date, the Company shall pay to the Executive a cash amount equal to the vested portion of the Retention Bonus Account as of the Termination Date.  The remainder of the Retention Bonus Account shall be forfeited.
 
	  
 
	            11.   Termination for Good Reason or Without Cause.  If the Executive’s
employment is terminated during the Employment Period (a) by the Executive for Good Reason or (b) by the Company other than by reason of death, disability pursuant to Section 13 hereof, or Cause (any such terminations to be subject to the procedures
set forth in Section 14 hereof), then the Executive shall be entitled to receive Termination Benefits pursuant to Section 9 and the following additional payments and benefits:
 
	  
 
	  
 	                 (i)     No later than five (5) days following the
Termination Date, the Company shall pay to the Executive the Retention Bonus Account as of the Termination Date;
 
	  
 
	  
 	                  (ii)    No later than five (5) days following the Termination
Date, the Company shall pay to the Executive the total amount of base salary payable to the Executive for the remainder of the Employment Period; and
 
	  
 	  
 
	  
 	                  (iii)   Immediately prior to the Termination Date, (x) each share of
Restricted Stock not then vested shall become fully vested and (y) each option to acquire Common Stock then held by the Executive (including the Option) shall become fully vested and exercisable as to all shares of Common Stock subject thereto and
shall remain exercisable for the remainder of such option’s original term.
 

  15

	           12.   Death.  In the event of the Executive’s death during the Employment Period, the
Executive’s estate, heirs and beneficiaries shall be entitled to receive Termination Benefits pursuant to Section 9, and shall not receive any compensation pursuant to Section 5 with respect to periods following the Termination Date. 
Immediately prior to the Termination Date, (x) each share of Restricted Stock not then vested shall become fully vested and (y) each option to acquire Common Stock then held by the Executive (including, the Option) shall become fully vested and
exercisable and shall remain exercisable for the remainder of such option’s original term.  In addition, no later than five (5) days following the Termination Date, the Company shall pay to the Executive the Retention Bonus Account as of
the Termination Date.
 
	  
 
	            13.   Termination for Disability.  If, during the Employment Period,  the Executive
incurs a disability, as defined in the Option Plan, and, within thirty days after the Company notifies the Executive in writing that it intends to terminate the Executive’s employment (which notice shall not constitute the Notice of Termination
contemplated below), the Executive shall not have returned to the performance of the Executive’s duties hereunder, the Company may terminate the Executive’s employment for purposes of this Agreement pursuant to a Notice of Termination
given in accordance with Section 14 hereof.  If the Executive’s employment is terminated on account of the Executive’s disability in accordance with this Section, the Executive shall be entitled to receive Termination Benefits
pursuant to Section 9 and the Executive shall not receive any compensation pursuant to Section 5 with respect to periods following the Termination Date.  Immediately prior to the Termination Date, (x) each share of Restricted Stock not then
vested shall become fully vested and (y) each option to acquire Common Stock then held by the Executive (including, the Option) shall become fully vested and exercisable and shall remain exercisable for the remainder of such option’s original
term.  In 
 

 16

	  addition, no later than five (5) days following the Termination Date, the Company shall pay to the Executive the Retention Bonus Account as of the Termination Date.

	  
 
	            14.   Termination Notice and Procedure.  Any termination by the Company or the Executive
during the Employment Period shall be communicated by written notice of termination (“Notice of Termination”) to the Executive, if such Notice is given by the Company, and to the Company, if such Notice is given by the Executive, all in
accordance with the following procedures and those set forth in Section 26 hereof.  Any Notice of Termination by the Company for Cause shall be accompanied by a resolution duly adopted by at least two thirds (2/3) of the directors of the
Company (or any successor corporation) at a meeting held for the purpose of considering such termination (after reasonable notice to the Executive and an opportunity for the Executive, together with the Executive’s counsel, to be heard before
the Board).
 
	  
 
	            15.   Excise Tax Gross-up.
 
	  
 
	                   (a)     If any of the payments or benefits
received or to be received by the Executive, whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement with the Company, Immunex Corporation, or any of their affiliates (all such payments and benefits, excluding the
Gross-Up Payment, being hereinafter referred to as the “Total Payments”) will be subject to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”), the Company shall pay to the Executive an additional amount
(the “Gross-Up Payment”) such that the net amount retained by the Executive, after deduction of any Excise Tax on the Total Payments and any federal, state and local income and employment taxes and Excise Tax upon the Gross-Up Payment, and
after taking into account the phase out of itemized 
 

  17

	  deductions and personal exemptions attributable to the Gross-Up Payment, shall be equal to the Total Payments.  The Gross-Up Payment shall be paid to the Executive no later
than the fifth day following the Termination Date (or if there is no Termination Date, then the date on which the Gross-Up Payment is calculated in accordance with this Section 15).
 
	  
 
	                   (b)     For purposes of determining whether
any of the Total Payments will be subject to the Excise Tax and the amount of such Excise Tax, (i) all of the Total Payments shall be treated as “parachute payments” (within the meaning of section 280G(b)(2) of the Code) unless, in the
opinion of tax counsel (“Tax Counsel”) reasonably acceptable to the Executive and selected by the accounting firm which is the Company’s independent auditor (the “Auditor”), such payments or benefits (in whole or in part) do
not constitute parachute payments, including by reason of section 280G(b)(4)(A) of the Code, (ii) all “excess parachute payments” within the meaning of section 280G(b)(l) of the Code shall be treated as subject to the Excise Tax unless, in
the opinion of Tax Counsel, such excess parachute payments (in whole or in part) represent reasonable compensation for services actually rendered (within the meaning of section 280G(b)(4)(B) of the Code) in excess of the base amount, within the
meaning of Section 2806(b)(3) of the Code (the “Base Amount”), allocable to such reasonable compensation, or are otherwise not subject to the Excise Tax, and (iii) the value of any noncash benefits or any deferred payment or benefit shall
be determined by the Auditor in accordance with the principles of sections 280G(d)(3) and (4) of the Code.  For purposes of determining the amount of the Gross-Up Payment, the Executive shall be deemed to pay federal income tax at the highest
marginal rate of federal income taxation in the calendar year in which the Gross-Up Payment is to be made and state and local income taxes at the highest marginal rate of taxation in the state 
 

 18

	  and locality of the Executive’s residence on the Termination Date, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state
and local taxes.
 
	  
 
	                    (c)     In the event that the Excise Tax is
finally determined to be less than the amount taken into account hereunder in calculating the Gross-Up Payment, the Executive shall repay to the Company, within five (5) business days following the time that the amount of such reduction in the
Excise Tax is finally determined, the portion of the Gross-Up Payment attributable to such reduction (plus that portion of the Gross-Up Payment attributable to the Excise Tax and federal, state and local income and employment taxes imposed on the
Gross-Up Payment being repaid by the Executive), to the extent that such repayment results in a reduction in the Excise Tax and a dollar-for-dollar reduction in the Executive’s taxable income and wages for purposes of federal, state and local
income and employment taxes, plus interest on the amount of such repayment at 120% of the rate provided in section 1274(b)(2)(B) of the Code.  In the event that the Excise Tax is determined to exceed the amount taken into account hereunder in
calculating the Gross-Up Payment (including by reason of any payment the existence or amount of which cannot be determined at the time of the Gross-Up Payment), the Company shall make an additional Gross-Up Payment in respect of such excess (plus
any interest, penalties or additions payable by the Executive with respect to such excess) within five (5) business days following the time that the amount of such excess is finally determined.  The Executive and the Company shall each
reasonably cooperate with the other in connection with any administrative or judicial proceedings concerning the existence or amount of liability for Excise Tax with respect to the Total Payments.
 

 19

	            16.     Confidentiality; Release; Other Agreements.
 
	  
 
	                     (a)     During and following the
Executive’s employment by the Company, the Executive shall hold in confidence and not directly or indirectly disclose or use or copy or make lists of any confidential information or proprietary data of the Company, except to the extent
authorized by the Board or required by any court or administrative agency, other than to an employee of the Company or a person to whom disclosure is reasonably necessary or appropriate in connection with the performance by the Executive of duties
as an executive of the Company.  Confidential information shall not include any information known generally to the public or any information of a type not otherwise considered confidential by persons engaged in the same business or a business
similar to that of the Company.  All records, files, documents and materials, or copies thereof, relating to the business of the Company which the Executive shall prepare, or use, or come into contact with, shall be and remain the sole property
of the Company and shall be promptly returned to the Company upon termination of employment with the Company.
 
	  
 
	                    (b)     Notwithstanding anything
contained herein, the Executive shall not be entitled to receive any payments or benefits under Section 9(b) or Section 11 hereof unless he first executes a written release substantially in the form attached hereto as Exhibit C and such release has
become effective.
 
	  
 
	                     (c)     The Executive shall execute,
prior to the Effective Date, the Proprietary Information and Inventions Agreement and the Mutual Agreement to Arbitrate Claims, in each case in the form generally used for senior Company executives (collectively, the “Ancillary 

  20

	  Agreements”), provided that notwithstanding anything in such Ancillary Agreements to the contrary, in case of conflicting provisions, the provisions of this Agreement shall
control.
 
	  
 
	            17.     Legal Fees and Expenses; Indemnification.
 
	  
 
	                    (a)     The Company also shall pay to
the Executive all legal fees and expenses incurred by the Executive (a) in disputing any issue hereunder relating to the termination of the Executive’s employment or in seeking to obtain or enforce any benefit or right provided by this
Agreement (in each case, unless the Executive is acting in bad faith) or (b) in connection with any tax audit or proceeding to the extent attributable to the application of section 4999 of the Code to any payment or benefit provided hereunder. 
Such payments shall be made within five (5) business days after delivery of the Executive’s written requests for payment accompanied with such evidence of fees and expenses incurred as the Company reasonably may require.
 
	  
 
	                     (b)     To the fullest extent permitted
by law, the Company shall indemnify the Executive (including the advancement of expenses) for any judgments, fines, amounts paid in settlement and reasonable expenses, including attorneys’ fees, incurred by the Executive in connection with the
defense of any lawsuit or other claim to which he is made a party by reason of being an officer, director or employee of the Company or any of its subsidiaries.  During the Employment Period and for at least three (3) years thereafter, the
Company shall use reasonable efforts to maintain customary director, officer and professional liability insurance covering the Executive for acts and omissions prior to and during the Employment Period.  The existence or lack of any such
insurance shall not limit the Company’s indemnification obligation.
 
	  
 
	           18.     No Set-Off or Counterclaim.  Except as expressly provided herein, the
amounts and benefits payable hereunder shall not be subject to set-off, counterclaim, recoupment, defense
 

  21

	  or other claim which the Company may have against him or anyone else.  Except as provided in Section 17 of this Agreement, all amounts payable by the Company
hereunder shall be paid without notice or demand.  Each and every payment made hereunder by the Company shall be final, and the Company will not seek to recover all or any part of such payment from the Executive, or from whomsoever may be
entitled thereto, for any reason whatsoever.
 
	  
 
	            19.     Successors.
 	  
 
	  
 	  
 
	                     (a)     If the Company
sells, assigns or transfers all or substantially all of its business and assets to any person or if the Company merges into or consolidates or otherwise combines (where the Company does not survive such combination) with any person (any such event,
a “Sale of Business”), then the Company shall cause such person, by written agreement in form and substance reasonably satisfactory to the Executive, to expressly assume and agree to perform from and after the date of such Sale of Business
all of the terms, conditions and provisions imposed by this Agreement upon the Company, and from and after such Sale of Business all references to the “Company” in this Agreement shall refer to such person.  Failure of the Company to
obtain such agreement prior to the effective date of such Sale of Business shall be a breach of this Agreement constituting “Good Reason” hereunder.  The Executive shall, in his discretion, be entitled to proceed against any or all of
such persons, any person which theretofore was such a successor to the Company (as defined in the first paragraph of this Agreement) and the Company (as so defined) in any action to enforce any rights of the Executive hereunder.  This Agreement
shall not be assignable by the Company except to any party to a Sale of Business that expressly assumes this Agreement as provided herein.  This Agreement shall not be terminated by the voluntary or involuntary dissolution of the
Company.
 

 22

	                     (b)     This Agreement and all rights
of the Executive shall inure to the benefit of and be enforceable by the Executive’s personal or legal representatives, executors, administrators, heirs and beneficiaries.  All amounts payable to the Executive under the Agreement if the
Executive had lived shall be paid, in the event of the Executive’s death, to the Executive’s estate, heirs and representatives; provided, however, that the foregoing shall not be construed to modify any terms of any benefit plan of the
Company that expressly govern benefits under such plan in the event of the Executive’s death.
 
	  
 
	            20.     Severability.  The provisions of this Agreement shall be regarded as
divisible, and if any of said provisions or any part hereof are declared invalid or unenforceable by a court of competent jurisdiction, the validity and enforceability of the remainder of such provisions or parts hereof and the applicability thereof
shall not be affected thereby.
 
	  
 
	            21.     Entire Agreement.  This Agreement, together with the Ancillary
Agreements, constitute the whole agreement of the Company and the Executive regarding the subject matter hereof.  No agreements or representation, oral or otherwise, express or implied, with respect to the subject matter of this Agreement have
been made by either party which are not expressly set forth in this Agreement or the Ancillary Agreements.  This Agreement shall supersede and replace the Original Agreement.
 
	  
 
	           22.     Amendment.  This Agreement may not be amended or modified at any time
except by written instrument executed by the Company and the Executive.
 
	  
 
	            23.     Withholding.  The Company shall be entitled to withhold from amounts to
by paid to the Executive hereunder any federal, state or local withholding or other taxes or charges which it is from time to time required to withhold.
 

  23

	            24.     Certain Rules of Construction.  No party shall be considered
as being responsible for the drafting of this Agreement for the purpose of applying any rule construing ambiguities against the drafter or otherwise.  No draft of this Agreement shall be taken into account in construing this Agreement. 
Any provision of this Agreement which requires an agreement in writing shall be deemed to require that the writing in question be signed by the Executive and an authorized representative of the Company.
 
	  
 
	           25.     Governing Law.  This Agreement and the rights and obligations
hereunder shall be governed by and construed in accordance with the laws of the State of Washington.
 
	  
 
	            26.     Notice.  Notices given pursuant to this Agreement shall be in
writing and shall be deemed given when actually received by the Executive or actually received by the Company’s Secretary.  If mailed, such notices shall be mailed by United States registered or certified mail, return receipt requested,
addressee only, postage prepaid, if to the Company, to the Secretary of the Company at its headquarters offices (currently located at Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA  91320-1797) or if the Executive, at the address set
forth below the Executive’s signature to this Agreement, or to such other address as the party to be notified shall have theretofore given to the other party in writing.
 
	  
 
	            27.     No Waiver.  No waiver by either party at any time of any
breach by the other party of, or compliance with, any condition or provision of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same time or any prior or subsequent
time.
 
	  
 	  
 
	           28.     Headings.  The headings herein contained are for reference
only and shall not affect the meaning or interpretation of any provision of this Agreement.
 

  24

	            29.     Counterparts.  This Agreement may be executed in counterparts all of which
shall be considered the same hereunder.
 
	  
 	  
 
	            30.     Survival.  The obligations of the parties set forth in Sections 1, 9, 10,
11, 12, 13, 15, 16, 17, 18, 19, 22 and 23 shall survive the termination of the Employment Period and of this Agreement.
 
	  
 
	                      IN WITNESS WHEREOF, the parties have executed this
Agreement as of the day and year first written above.
 
	  
 
	  
 	 /s/ BRIAN MCNAMEE
 	  
 	  /s/ EDWARD V. FRITZKY
 	  
 
	  
 	 
 	  
 	 
 	  
 
	  AMGEN INC.
 	 	  
 	  EDWARD V. FRITZKY
 	  
 
	 By:
 	  Brian McNamee
 	  
 	  
 	  
 
	 Title:
 	  Senior Vice President,
 Human Resources
 	  
 	  
 	  
 

  25

	  EXHIBIT C
 
	  
 
	  WAIVER AND RELEASE OF CLAIMS AGREEMENT
 
	  
 
	            YOU HAVE BEEN ADVISED TO CONSULT AN ATTORNEY PRIOR TO SIGNING THIS AGREEMENT.
 
	  
 
	            YOU MAY NOT SIGN THIS SETTLEMENT AGREEMENT AND GENERAL RELEASE BEFORE YOU TERMINATE EMPLOYMENT.
 
	  
 
	            YOU HAVE [FORTY-FIVE] [TWENTY-ONE] DAYS AFTER RECEIVING THIS AGREEMENT TO CONSIDER WHETHER TO SIGN IT, ALTHOUGH YOU
MAY WAIVE THIS TIME PERIOD BY SIGNING IT SOONER.
 
	  
 
	           AFTER SIGNING THIS AGREEMENT, YOU HAVE ANOTHER SEVEN DAYS IN WHICH TO REVOKE IT, AND IT DOES NOT TAKE EFFECT UNTIL
THOSE SEVEN DAYS HAVE ENDED.
 
	  
 
	            1.  In consideration of, and subject to, the payments to be made to me pursuant to the Employment Agreement
between me and Amgen Inc. (the “Employment Agreement”), the adequacy of which is hereby acknowledged, and which I acknowledge that I would not otherwise be entitled to receive, on behalf of myself and my heirs, representatives, executors,
administrators, successors, agents, and assigns,  I hereby agree to and hereby do fully, completely, unconditionally, and without limitation release, acquit, and forever discharge Amgen Inc., all related or affiliated companies, and all of its
or such related or affiliated companies predecessors, successors, assigns, and parents (collectively the “Company”) and with respect to each such entity, its present and former shareholders, parents, owners, officers, directors, agents,
partners, joint venturers, employees, servants, independent contractors, customers, consultants, insurers, representatives, lawyers, employee benefit programs (and the trustees, administrators, fiduciaries and insurers of such programs), and all
persons acting by, through, under, or in concert with them, or any of them (“Releasees”), both individually and collectively, of and from any and all manner of action or actions, cause or causes of action, suits, rights, claims, debts,
liens, demands, contracts, promises, agreements, liabilities, claims, damages, losses, costs, expenses, compensation, attorneys’ fees, indemnities, and obligations of every kind and nature, in law, equity, or otherwise, known or unknown,
suspected or unsuspected, disclosed and undisclosed, fixed or contingent (hereinafter called “Claims”), which I have, may have, or now claim to have, from the Releasees by reason of any matter, cause, or thing whatsoever, from the
beginning of time to the date hereof, including, without limiting the generality of the foregoing, any Claims arising out of, based upon, or relating to my recruitment, hire, employment, relocation, benefits, remuneration, or termination by the
Releasees, or any of them.  As part of this Agreement, I expressly release and waive any and all Claims arising out of any contract, tort or other common-law theories, and any Claims under any local, state or federal civil rights, labor, and
employment laws, including but not limited to the Employee Retirement Income Security Act (ERISA), Title VII of the Civil Rights Act of 1964, the Post Civil War Civil Rights Acts (42 U.S.C. §§ 1981-1988), the Civil Rights Act of 1991, the
Equal Pay Act, the Age Discrimination in Employment Act (“ADEA”), the Americans with Disabilities Act, the Older
 

	  Workers’ Benefit Protection Act (“OWBPA”), the Worker Adjustment and Retraining Notification Act, the Rehabilitation Act of 1973, the Vietnam Veterans Readjustment
Assistance Act, the Uniformed Services Employment and Reemployment Rights Act, the Fair Labor Standards Act, Executive Order 11246, the Family and Medical Leave Act, the civil rights, employment and wage and hour laws of the State of Washington
including, but not limited to, RCW 49.48, 49.52, and 49.60 (all statutes as amended), or any other federal, state or local law, ordinance, rule, or regulation of any kind, including but not limited to those governing employment, discrimination in
employment, termination of employment, or the payment of wages and benefits.
 
	  
 
	            2.  Notwithstanding the foregoing or any other provision hereof, nothing in this Waiver and Release of
Claims Agreement (this “Agreement”) shall adversely affect (i) any Claims I may have under the ADEA which may arise after I sign this Agreement; (ii) my rights under the Employment Agreement; (iii) my rights to any vested benefits other
than severance benefits to which I may be entitled under plans, programs and arrangements of the Company or any subsidiary or parent of the Company; (iv) my rights to indemnification, if any, under any indemnification agreement, applicable law and
the certificates of incorporation and bylaws or comparable organizational documents of Immunex and any subsidiary or parent of Immunex; and (v) my rights, if any, under any director’s and officer’s liability insurance policy or
professional malpractice insurance policy covering me.
 
	  
 
	           3.  I understand that my employment with the Company has terminated forever and I promise never to seek
employment with the Company.
 
	  
 
	            4.  I acknowledge that I have signed this Agreement voluntarily, knowingly, of my own free will and without
reservation or duress, and that no promises or representations, written or oral, have been made to me by any person to induce me to do so other than the promise of payment set forth in paragraph 1 (one) above and the Company’s acknowledgment of
my rights reserved under the paragraph 2 (two) above.
 
	  
 
	            5.  I acknowledge that I have been given not less than [forty-five (45)] [twenty-one (21)] days to review
and consider this Agreement.  I waive any right I might have to additional time beyond this consideration period within which to consider this Agreement.  I may revoke this Agreement seven days or less after its execution by providing
written notice to the Vice President of Human Resources of the Company or its parent or successor.
 
	  
 
	            6.  I acknowledge that I have had the opportunity to consult with an attorney or other advisor of my choice,
at my own expense, and have been advised by the Company or its parent or successor to do so if I choose.
 
	  
 
	           7.  For a period of one year after the date of termination of my employment, I agree not to criticize,
denigrate or otherwise disparage the Company, any other Releasee, or any of the Company’s products, processes, experiments, policies, practices, standards of business conduct, or areas or techniques of research; provided, however, that nothing
in this Agreement shall prohibit me from complying with any lawful subpoena or court order.
 

  2

	            8.  The provisions of this Agreement are severable.  If any part of it is found to be unenforceable,
all other provisions shall remain fully valid and enforceable.
 
	  
 
	            9.  This Agreement shall inure to the benefit of all Releasees and their respective heirs, administrators,
representatives, executors, successors, and assigns.
 
	  
 
	            10.  I represent and warrant that I have not assigned or transferred, or purported to assign or transfer,
all or any part of any Claim released by this Agreement.  I represent and warrant that I have not filed or caused to be filed any lawsuit, complaint, or charge with respect to any Claim released in this Agreement, and I promise never to file or
prosecute a lawsuit or other complaint or charge asserting any Claims that are released in this Agreement.  I promise never to seek any damages, remedies, or other relief for myself personally (any right to which I hereby waive and promise
never to accept) by filing or prosecuting a charge with any administrative agency with respect to any Claim purportedly released by this Agreement.  I promise never directly or indirectly to bring or participate in an action against any
Releasee under California Business & Professions Code Section 17200 or under any other unfair competition law of any jurisdiction.  This paragraph 8 shall not apply to ADEA claims if applying it would violate the ADEA or OWBPA.

	  
 
	           11.  I represent and warrant that I am not aware of any facts that would (a) establish, (b) tend to
establish, or (c) in any way support an allegation of a violation by the Company of the federal False Claims Act (or any similar state or federal qui tam statute).  In addition, in order to ensure that I have complied fully with
my obligations under this paragraph 9, I hereby covenant and agree that to the full extent permitted by law, I hereby waive and release any and all rights or claims I may have to any proceeds or awards that I may be entitled to under any qui
tam proceeding brought against the Company.  I further agrees that I shall deliver any such money, proceeds, or awards to the U.S. government.
 
	  
 
	            12.  This Agreement shall be governed and interpreted under federal law and the laws of the State of
Washington as applied to contracts entered into and to be performed entirely within such state by residents thereof.
 
	  
 
	            13.  Finally, I acknowledge that I have carefully read this Agreement and fully understand all of its
terms.  Except as set forth herein, this is the entire agreement between the parties; it may not be modified or canceled in any manner except by a writing signed by both Immunex or its parent or successor and me.  This Agreement is legally
binding and enforceable.
 

 3

	            I KNOWINGLY AND VOLUNTARILY SIGN THIS WAIVER AND RELEASE OF CLAIMS AGREEMENT.
 
	  
 
	  
 	  Signed: 
 	  /s/ EDWARD V. FRITZKY
 	  
 
	  
 	  
 	 
 	  
 
	  
 	  
 	  
 	  
 
	  
 	  Date:  
 	  January 2, 2003
 	  
 
	  
 	  
 	 
 	  
 
	  
 	  
 	  
 	  
 
	  
 	  
 	  
 	  
 
	  
 	  
 	 
 	  
 
	   
 	   
 	 Edward V. Fritzky
 	   
 
	  
 	  
 	  
 
	  
 	  AMGEN INC.
 	  
 
	  
 	  
 	  
 
	  
 	  By: 
 	  Brian McNamee
 	  
 
	  
 	  Title: 
 	  Senior Vice President, Human Resources
 	  
 
	  
 	  Date: 
 	 January 2, 2003
 	  
 	  
 
						

  4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}]]